Cargando…

A systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma

BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphoma of the thymus is a rare disease. The present meta-analysis aims at accumulating current evidence to explore the clinical characteristics, treatments, and prognoses of thymic MALT lymphoma. METHODS: We searched seven databases for studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Meng-Xin, Chen, Ye-Ye, Zhang, Jia-Qi, Bai, Wen-Liang, Huang, Cheng, Guo, Chao, Liu, Hong-Sheng, Li, Shan-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442531/
https://www.ncbi.nlm.nih.gov/pubmed/36071772
http://dx.doi.org/10.21037/jtd-22-81
_version_ 1784782834228002816
author Zhou, Meng-Xin
Chen, Ye-Ye
Zhang, Jia-Qi
Bai, Wen-Liang
Huang, Cheng
Guo, Chao
Liu, Hong-Sheng
Li, Shan-Qing
author_facet Zhou, Meng-Xin
Chen, Ye-Ye
Zhang, Jia-Qi
Bai, Wen-Liang
Huang, Cheng
Guo, Chao
Liu, Hong-Sheng
Li, Shan-Qing
author_sort Zhou, Meng-Xin
collection PubMed
description BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphoma of the thymus is a rare disease. The present meta-analysis aims at accumulating current evidence to explore the clinical characteristics, treatments, and prognoses of thymic MALT lymphoma. METHODS: We searched seven databases for studies published between the start date of database establishment and September 15, 2021. We included studies of patients with histological diagnoses and excluded those without data specifically on thymic MALT lymphoma. The quality was analyzed using an assessment tool. All data were tabulated. Pooled proportion was obtained using random-effects model. Statistical analysis was performed on R statistic software. RESULTS: Overall, 52 case reports and 13 case series were eligible. The quality of case reports was inferior to that of case series in terms of selection (P<0.001). Based on the analysis of patients in the case reports, age, gender, concurrent diseases, and tumor size did not differ between limited-stage and advanced-stage cases. Surgery is the mainstay to treat thymic MALT lymphoma. The surgical approach and extent did not influence the occurrence of events. Patients at Ann Arbor stage I were prone to not receiving postoperative therapy (P=0.011), though it may not reduce the occurrence of events (P=0.637). The five-year overall survival (OS) rate and five-year progression-free survival (PFS) rate were 97.2% and 88.4%, respectively. Patients with advanced-stage disease were more likely to suffer events (P=0.009). CONCLUSIONS: Thymic MALT lymphoma is an extremely rare disease with a favorable prognosis. Currently available evidence is insufficient to draw solid judgments about treatment and prognosis. However, patients may benefit if thymectomy is chosen as the primary treatment. In some patients, lymph node sampling or dissection should be considered. In addition, if the patient is at an advanced-stage, postoperative therapy should be considered.
format Online
Article
Text
id pubmed-9442531
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-94425312022-09-06 A systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma Zhou, Meng-Xin Chen, Ye-Ye Zhang, Jia-Qi Bai, Wen-Liang Huang, Cheng Guo, Chao Liu, Hong-Sheng Li, Shan-Qing J Thorac Dis Original Article BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphoma of the thymus is a rare disease. The present meta-analysis aims at accumulating current evidence to explore the clinical characteristics, treatments, and prognoses of thymic MALT lymphoma. METHODS: We searched seven databases for studies published between the start date of database establishment and September 15, 2021. We included studies of patients with histological diagnoses and excluded those without data specifically on thymic MALT lymphoma. The quality was analyzed using an assessment tool. All data were tabulated. Pooled proportion was obtained using random-effects model. Statistical analysis was performed on R statistic software. RESULTS: Overall, 52 case reports and 13 case series were eligible. The quality of case reports was inferior to that of case series in terms of selection (P<0.001). Based on the analysis of patients in the case reports, age, gender, concurrent diseases, and tumor size did not differ between limited-stage and advanced-stage cases. Surgery is the mainstay to treat thymic MALT lymphoma. The surgical approach and extent did not influence the occurrence of events. Patients at Ann Arbor stage I were prone to not receiving postoperative therapy (P=0.011), though it may not reduce the occurrence of events (P=0.637). The five-year overall survival (OS) rate and five-year progression-free survival (PFS) rate were 97.2% and 88.4%, respectively. Patients with advanced-stage disease were more likely to suffer events (P=0.009). CONCLUSIONS: Thymic MALT lymphoma is an extremely rare disease with a favorable prognosis. Currently available evidence is insufficient to draw solid judgments about treatment and prognosis. However, patients may benefit if thymectomy is chosen as the primary treatment. In some patients, lymph node sampling or dissection should be considered. In addition, if the patient is at an advanced-stage, postoperative therapy should be considered. AME Publishing Company 2022-08 /pmc/articles/PMC9442531/ /pubmed/36071772 http://dx.doi.org/10.21037/jtd-22-81 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Zhou, Meng-Xin
Chen, Ye-Ye
Zhang, Jia-Qi
Bai, Wen-Liang
Huang, Cheng
Guo, Chao
Liu, Hong-Sheng
Li, Shan-Qing
A systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma
title A systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma
title_full A systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma
title_fullStr A systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma
title_full_unstemmed A systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma
title_short A systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma
title_sort systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442531/
https://www.ncbi.nlm.nih.gov/pubmed/36071772
http://dx.doi.org/10.21037/jtd-22-81
work_keys_str_mv AT zhoumengxin asystematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT chenyeye asystematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT zhangjiaqi asystematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT baiwenliang asystematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT huangcheng asystematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT guochao asystematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT liuhongsheng asystematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT lishanqing asystematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT zhoumengxin systematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT chenyeye systematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT zhangjiaqi systematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT baiwenliang systematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT huangcheng systematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT guochao systematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT liuhongsheng systematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma
AT lishanqing systematicreviewandmetaanalysisofthymicmucosaassociatedlymphoidtissuelymphoma